Gilead Sciences Inc. will acquire Forty Seven Inc. for $4.9 billion, or $95.50 per share in cash, bringing Gilead magrolimab, an anti-CD47 monoclonal antibody being developed to treat several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL).
LONDON – Immunocore Ltd. has closed a series B round that will bring in more than $130 million, breathing fresh energy into its T-cell receptor programs in cancer and extending the reach of the technology into infectious and autoimmune diseases.
RSS
